Drugs / Mangafodipir
Mangafodipir
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Teslascan | — | 2012-06-21 | europa.eu ↗ |
| Approved | EU (EMA) | Teslascan | — | 1997-05-22 | europa.eu ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02531880 | Nov 2024 → Jul 2030 expected | epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06731738 | Nov 2024 → Nov 2025 | diastolic heart failure | IC TARGETS AS | Completed | No outcome recorded |
| Phase 2 | NCT00727922 | Jun 2008 → Jan 2010 | cancer, toxic polyneuropathy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01326715 Comparator | Oct 2013 → Sep 2019 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00966563 Comparator | Dec 2009 → May 2013 | myocardial infarction | Egetis Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00671996 Comparator | Jun 2008 → Apr 2010 | colon carcinoma | Egetis Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-02-01 | IC TARGETS AS | Results Mangafodipir preclinical results presented at ECR 2024 ictargets.com ↗
The study revealed that the uptake rate constant for manganese is much lower in pigs than in humans; this finding was unexpected and may be related to the low cardiomyocyte T-tubulus density in pigs. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-20 | IC TARGETS AS | IC Targets AS completes last patient visit in Phase 2A mangafodipir trial ictargets.com ↗ |
| 2025-02-13 | IC TARGETS AS | Phase 2A trial in heart failure: first patients dosed with mangafodipir ictargets.com ↗ |
| 2024-10-01 | IC TARGETS AS | Mangafodipir preclinical study results shared at CMR Symposium, Oslo ictargets.com ↗ |
| 2024-02-01 | IC TARGETS AS | Mangafodipir preclinical results presented at ECR 2024 ictargets.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mangafodipir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00966563 ↗ |
| Known as | Anhydrous mangafodipir trisodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | Magnafodipir sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | MANGAFODIPIR TRISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | Mangafodipir trisodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | Mangafodipir trisodium, anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | NSC-760070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Known as | PP-099 | “The present feasibility study is designed to find out whether pre-treatment with the compound mangafodipir (PP-099) provides an additional reduction in myocardial infarct size...” NCT00966563 ↗ |
| Known as | Teslascan | “Mangafodipir (Teslascan)” NCT01326715 ↗ |
| Known as | WIN 59010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201301 ↗ |
| Modality | Diagnostic / imaging agent | “Mangafodipir is a MRI contrast agent” NCT00727922 ↗ |
| Route | Intravenous | “will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.” NCT00671996 ↗ |